Industry News

  • Everything You Need To Know About Doxycycline Hyclate

    Everything You Need To Know About Doxycycline Hyclate

    Doxycycline hyclate, commonly known as doxycycline, is the most frequently used antibacterial drug in veterinary clinical diagnosis. No one can simply judge which one is better between it and fluphenazole. In the veterinary market, o...
    Read more
  • Learn About Pregabalin+Nortriptyline

    Learn About Pregabalin+Nortriptyline

    Pregabalin and Nortriptyline tablets, a combination of two drugs, Pregabalin (anti-convulsant) and Nortriptyline (antidepressant), is used to treat neuropathic pain (a sensation of numbness, tingling and also feels like pins and needles). Pregabalin helps to decrease pai...
    Read more
  • How To Use Thalidomide To Help Develop New Cancer Therapies

    How To Use Thalidomide To Help Develop New Cancer Therapies

    The drug thalidomide was recalled in the 1960s because it caused devastating defects in newborns, but at the same time it was widely used to treat multiple sclerosis and other blood cancers, and can, with its chemical relatives, promote cellular destruction of two specif...
    Read more
  • Everything You Need Know About Pregabalin And Methylcobalamin Capsules

    What are pregabalin and methylcobalamin capsules? Pregabalin and methylcobalamin capsules are a combination of two medicines: pregabalin and methylcobalamin. Pregabalin acts by decreasing the number of pain signals sent by a damaged nerve in the body, and meth...
    Read more
  • Bayer’s new heart drug Vericiguat is approved in China

    On May 19, 2022, China’s National Medical Products Administration (NMPA) approved the marketing application for Bayer’s Vericiguat (2.5 mg, 5 mg, and 10 mg) under the brand name Verquvo™. This drug is used in adult patients with symptomatic chronic heart failure and red...
    Read more
  • Three major differences between Ruxolitinib and Ruxolitinib cream

    Three major differences between Ruxolitinib and Ruxolitinib cream

    Ruxolitinib is a type of oral targeted therapy called a kinase inhibitor and is mainly used to treat diseases such as graft-versus-host disease, erythroblastosis, and medium-and high-risk myelofibrosis, while Ruxolitinib cream is a topical dermatological agent that is ap...
    Read more
  • Ruxolitinib significantly reduces disease and improves quality of life in patients

    Ruxolitinib significantly reduces disease and improves quality of life in patients

    The treatment strategy for primary myelofibrosis (PMF) is based on risk stratification. Due to the variety of clinical manifestations and issues to be addressed in PMF patients, treatment strategies need to take into acco...
    Read more
  • Heart disease needs a new drug – Vericiguat

    Heart disease needs a new drug – Vericiguat

    Heart failure with reduced ejection fraction (HFrEF) is a major type of heart failure, and the China HF Study showed that 42% of heart failures in China are HFrEF, although several standard therapeutic classes of drugs are available for HFrEF and have reduced the risk of...
    Read more
  • Changzhou Pharmaceutical received approval to produce Lenalidomide Capsules

    Changzhou Pharmaceutical received approval to produce Lenalidomide Capsules

    Changzhou Pharmaceutical Factory Ltd., a subsidiary of Shanghai Pharmaceutical Holdings, received the Drug Registration Certificate (Certificate No. 2021S01077, 2021S01078, 2021S01079) issued by the State Drug Administration for Lenalidomide Capsules (Specification 5mg, ...
    Read more
  • What are the precautions for rivaroxaban tablets?

    What are the precautions for rivaroxaban tablets?

    Rivaroxaban, as a new oral anticoagulant, has been widely used in the prevention and treatment of venous thromboembolic diseases. What do I need to pay attention to when taking rivaroxaban? Unlike warfarin, rivaroxaban does not require monitoring of blood clotting indica...
    Read more
  • 2021 FDA New Drug Approvals 1Q-3Q

    Innovation drives progress. When it comes to innovation in the development of new drugs and therapeutic biological products, FDA's Center for Drug Evaluation and Research (CDER) supports the pharmaceutical industry at every step of the process. With its understanding of ...
    Read more
  • Recent developments of Sugammadex Sodium in the wake period of anesthesia

    Recent developments of Sugammadex Sodium in the wake period of anesthesia

    Sugammadex Sodium is a novel antagonist of selective non-depolarizing muscle relaxants (myorelaxants), which was first reported in humans in 2005 and has since been used clinically in Europe, the United States and Japan. Compared with traditional anticholinesterase drugs...
    Read more
12 Next > >> Page 1 / 2